Akarsu, MesutOnem, SonerTuran, IlkerAdali, GupseAkdogan, MeralAkyildiz, MuratAladag, Murat2024-08-042024-08-0420212148-5607https://doi.org/10.5152/tjg.2021.21608https://search.trdizin.gov.tr/yayin/detay/512595https://hdl.handle.net/11616/92613The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.eninfo:eu-repo/semantics/openAccessHepatitis Bliver transplantationrecurrenceReview Article3297127193460929910.5152/tjg.2021.216082-s2.0-85117952374Q3512595WOS:000703346600001Q4